ESMO 2023 | DAD: sacituzumab govetican + enfortumab vedotin as a 2L therapy for mUC

Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, provides an overview of the DAD trial (NCT04724018), a Phase I study evaluating the safety and efficacy of sacitizumab govetican and enfortumab vedotin as a second-line therapy in patients with metastatic urothelial carcinoma. The combination was safe and well tolerated in patients and resulted in an overall response rate of 71% in patients with treatment-refractory urothelial carcinoma, highlighting the potential for rational combinations of antibody-drug conjugates. Further exploration of this combination with immunotherapy will be investigated. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.